Ivax Says Paclitaxel Will Stay On Market Despite Appeals Court Ruling
Executive Summary
FDA does not want to remove generic versions of Bristol-Myers Squibb's Taxol from the market, Ivax maintained following an appeals court ruling directing the agency to vacate the approval of Ivax' ANDA for paclitaxel
You may also be interested in...
Ivax Paclitaxel Will Remain On Market; Taxol Generic Has 40% Share
Ivax' generic paclitaxel has taken just 40% of the paclitaxel market, in part because Bristol-Myers Squibb has reduced the price of Taxol significantly, Ivax said in a Jan. 15 citizen petition submitted to FDA
Ivax Paclitaxel Will Remain On Market; Taxol Generic Has 40% Share
Ivax' generic paclitaxel has taken just 40% of the paclitaxel market, in part because Bristol-Myers Squibb has reduced the price of Taxol significantly, Ivax said in a Jan. 15 citizen petition submitted to FDA
Bristol De-Lists ABI Taxol Patent Under Settlement With Ivax
Bristol-Myers Squibb is de-listing the American BioSciences paclitaxel patent that threatened the continued marketing of generic versions of Taxol